5-Methoxy-diisopropyltryptamine

5-methoxy-diisopropyltryptamine, also known as 5-methoxy-N,N-diisopropyltryptamine, 5-MeO-DiPT, foxy methoxy, or just foxy, is a tryptamine that is used recreationally as a psychedelic. 5-MeO-DiPT is orally active, and dosages between 6–20 mg are commonly reported. Many users note an unpleasant body load accompanies higher dosages. 5-MeO-DiPT is also taken by insufflation, or sometimes it is smoked or injected. Some users also report sound distortion, also noted with the related drug, DiPT.

Effects
Erowid reports the following effects:

Positive

 * Mood lift, euphoria
 * Intensification of tactile sensations, smell, etc
 * Sexually interesting
 * Emotionally opening

Neutral

 * Feelings of body & muscle energy, buzzing
 * Auditory distortions, pitch shifts
 * Visual distortions, open and closed-eye patterning, movement trails, shifting colors
 * Physical and mental stimulation

Negative

 * Possible stomach discomfort, gas & vomiting
 * Possible minor jaw-clenching
 * Possible Diarrhea
 * Anxious stimulation
 * Muscle tension / discomfort
 * Possible insomnia for 4-12 hours after peak
 * Possible male impotence for duration of drug's effects during higher doses

Legality
5-MeO-DIPT has been illegal in Germany since September 1999, Greece since February 2003, Denmark since February 2004, Sweden since October 2004, Japan since April 2005, and Singapore since early 2006.

On April 4, 2003, the United States DEA added both 5-MeO-DiPT and AMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004.

Prior to its prohibition in the U.S., 5-MeO-DIPT was sold online alongside psychoactive analogues like DIPT, DPT, and 5-MeO-DMT, none of which have yet been expressly outlawed in that country. However, in July 2004, Operation Web Tryp was concluded, confirming that U.S. Federal law enforcement intends to prosecute sale of these analogs of 5-MeO-DIPT. Previous prosecutions under the Federal Analog Act have met, on occasion, with failure, given some court rulings regarding possible unconstitutional vagueness regarding what substances are properly considered 'analogs'; such issues may be addressed on appeal.